Insider · CIK 0001597585

Eastman Ronald W

Reports to the SEC for 6 companies · PALO ALTO, CA

sec.gov

Transactions

Companies

Filings

CIK

0001597585

Forms 4 and 5

Insider transactions

35 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2018-11-27	Corium International, Inc.U Disposition from Tender	Director, 10% Owner	UDisposition from Tender	−9.35M sh	$12.50	−$117M	0
2018-11-27	Corium International, Inc.Director Stock Option (Right to Buy)D Disposition to Issuer	Director, 10% Owner	DDisposition to Issuer	−20K sh	$12.50	−$250K	0
2018-11-27	Corium International, Inc.Director Stock Option (Right to Buy)D Disposition to Issuer	Director, 10% Owner	DDisposition to Issuer	−15K sh	$12.50	−$188K	0
2018-11-27	Corium International, Inc.Director Stock Option (Right to Buy)D Disposition to Issuer	Director, 10% Owner	DDisposition to Issuer	−15K sh	$12.50	−$188K	0
2017-12-01	Corium International, Inc.Director Stock Option (Right to Buy)A Award	Director, 10% Owner	AAward	+15K sh	—	—	15,000
2017-05-11	Revance Therapeutics, Inc.A Award	Director, 10% Owner	AAward	+3,000 sh	—	—	3,000
2017-05-11	Revance Therapeutics, Inc.Stock Option (Right to Buy)A Award	Director, 10% Owner	AAward	+6,000 sh	—	—	6,000
2016-12-22	Corium International, Inc.Director Stock Option (Right to Buy)A Award	Director, 10% Owner	AAward	+15K sh	—	—	15,000
2016-05-05	Revance Therapeutics, Inc.Stock Option (Right to Buy)A Award	Director, 10% Owner	AAward	+8,000 sh	—	—	8,000
2015-12-18	Corium International, Inc.Director Stock Option (right to buy)A Award	Director, 10% Owner	AAward	+20K sh	—	—	20,000
2015-05-07	Revance Therapeutics, Inc.Stock Option (Right to Buy)A Award	Director, 10% Owner	AAward	+8,000 sh	—	—	8,000
2014-02-11	Revance Therapeutics, Inc.C Conversion	Director, 10% Owner	CConversion	+2.78M sh	—	—	2,781,396
2014-02-11	Revance Therapeutics, Inc.C Conversion	Director, 10% Owner	CConversion	+597K sh	—	—	3,378,208
2014-02-11	Revance Therapeutics, Inc.X Exercise of In-Money	Director, 10% Owner	XExercise of In-Money	+369K sh	—	—	3,747,332
2014-02-11	Revance Therapeutics, Inc.C Conversion	Director, 10% Owner	CConversion	+201K sh	—	—	200,538
2014-02-11	Revance Therapeutics, Inc.C Conversion	Director, 10% Owner	CConversion	+43K sh	—	—	243,567
2014-02-11	Revance Therapeutics, Inc.X Exercise of In-Money	Director, 10% Owner	XExercise of In-Money	+26.6K sh	—	—	270,172
2014-02-11	Revance Therapeutics, Inc.C Conversion	Director, 10% Owner	CConversion	+87.2K sh	—	—	87,190
2014-02-11	Revance Therapeutics, Inc.C Conversion	Director, 10% Owner	CConversion	+18.7K sh	—	—	105,898
2014-02-11	Revance Therapeutics, Inc.X Exercise of In-Money	Director, 10% Owner	XExercise of In-Money	+11.6K sh	—	—	117,458
2014-02-11	Revance Therapeutics, Inc.Series E-3 Convertible Preferred StockC Conversion	Director, 10% Owner	CConversion	−575K sh	—	—	0
2014-02-11	Revance Therapeutics, Inc.Series E-4 Convertible Preferred StockC Conversion	Director, 10% Owner	CConversion	−1.8M sh	—	—	0
2014-02-11	Revance Therapeutics, Inc.Series E-5 Convertible Preferred StockC Conversion	Director, 10% Owner	CConversion	−404K sh	—	—	0
2014-02-11	Revance Therapeutics, Inc.Convertible Promissory NotesC Conversion	Director, 10% Owner	CConversion	−597K sh	—	—	0
2014-02-11	Revance Therapeutics, Inc.Warrant to Purchase Common StockX Exercise of In-Money	Director, 10% Owner	XExercise of In-Money	−369K sh	—	—	0
2014-02-11	Revance Therapeutics, Inc.Series E-3 Convertible Preferred StockC Conversion	Director, 10% Owner	CConversion	−41.5K sh	—	—	0
2014-02-11	Revance Therapeutics, Inc.Series E-4 Convertible Preferred StockC Conversion	Director, 10% Owner	CConversion	−130K sh	—	—	0
2014-02-11	Revance Therapeutics, Inc.Series E-5 Convertible Preferred StockC Conversion	Director, 10% Owner	CConversion	−29.1K sh	—	—	0
2014-02-11	Revance Therapeutics, Inc.Convertible Promissory NotesC Conversion	Director, 10% Owner	CConversion	−43K sh	—	—	0
2014-02-11	Revance Therapeutics, Inc.Warrant to Purchase Common StockX Exercise of In-Money	Director, 10% Owner	XExercise of In-Money	−26.6K sh	—	—	0
2014-02-11	Revance Therapeutics, Inc.Series E-3 Convertible Preferred StockC Conversion	Director, 10% Owner	CConversion	−18K sh	—	—	0
2014-02-11	Revance Therapeutics, Inc.Series E-4 Convertible Preferred StockC Conversion	Director, 10% Owner	CConversion	−56.5K sh	—	—	0
2014-02-11	Revance Therapeutics, Inc.Series E-5 Convertible Preferred StockC Conversion	Director, 10% Owner	CConversion	−12.7K sh	—	—	0
2014-02-11	Revance Therapeutics, Inc.Convertible Promissory NotesC Conversion	Director, 10% Owner	CConversion	−18.7K sh	—	—	0
2014-02-11	Revance Therapeutics, Inc.Warrant to Purchase Common StockX Exercise of In-Money	Director, 10% Owner	XExercise of In-Money	−11.6K sh	—	—	0

Recent filings

Accepted (ET)
Nov 294
Eastman Ronald W0001567619-18-007097
SEC(opens sec.gov)
Dec 54
Eastman Ronald W0001140361-17-045104
SEC(opens sec.gov)
May 124
Revance Therapeutics, Inc.0001209191-17-032205
SEC(opens sec.gov)
Dec 274
Corium International, Inc.0001140361-16-090850
SEC(opens sec.gov)
May 94
Revance Therapeutics, Inc.0001209191-16-118611
SEC(opens sec.gov)
Dec 224
Corium International, Inc.0001140361-15-045351
SEC(opens sec.gov)
May 144
Revance Therapeutics, Inc.0001209191-15-043019
SEC(opens sec.gov)
Feb 114
Revance Therapeutics, Inc.0001209191-14-009025
SEC(opens sec.gov)

Companies

Address

C/O ESSEX WOODLANDS HEALTH VENTURES 335 BRYANT STREET, THIRD FLOOR

PALO ALTO, CA, 94301